Systemic Lymphadenectomy Cannot Be Recommended for Low-Risk Corpus Cancer

Table 1

Patients characteristics (𝑛=83).

Age (years)
Mean ± SD	56.2±12.1
Median	55
Range	27–80
WHO* performance status, no.
0	59
1	14
>2	0
FIGO** surgical stage, no.
Ia	32
Ib	43
Ic	3
IIIa	5
Adjuvant chemotherapy, no.
None	74
Paclitaxel/carboplatin^§	9
Follow up interval (months)
Median (range)	72 (4–120)

WHO*: World Health Organization, FIGO**: International Federation of Gynecology and Obstetrics Paclitaxel/carboplatin ^§: Paclitaxel (180 mg/m²) and carboplatin (area under the curve; AUC 5).